Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience
Vaccination against COVID-19 is safe and effective for patients affected by hemoglobinopathies, ensuring adequate protection from severe infection.
Authors
- Anna Bulla
- Alessandra Romano (ORCID: https://orcid.org/0000-0002-6333-4433)
- Benedetta Ximenes
- Giuseppe A. Palumbo (ORCID: https://orcid.org/0000-0003-1859-6319)
- Rosamaria Rosso
- Cesarina Giallongo (ORCID: https://orcid.org/0000-0002-7667-6088)
- Daniele Tibullo (ORCID: https://orcid.org/0000-0002-4416-8556)
- Enrico La Spina (ORCID: https://orcid.org/0000-0002-8483-4680)
- Daniela Cambria
- Andrea Duminuco (ORCID: https://orcid.org/0000-0002-9510-4755)
- Francesco Di Raimondo
- M. A. Romeo (ORCID: https://orcid.org/0009-0008-8081-8932)
Institutions
- University of Catania (IT)
- Policlinico Universitario di Catania (IT)
- Tecnologie Avanzate (Italy) (IT)
Publication Details
- Journal
- Vaccines
- Published
- 2025-01-23
- DOI
- https://doi.org/10.3390/vaccines13020111
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.19